Latest

Oct 09, 2017
Pharmaceutical Executive
What is the true potential of real-world evidence studies and what are the right questions to ask in determining product performance in the marketplace?
Oct 06, 2017
TESARO president and COO Mary Lynne Hedley talks about responsible drug development and commercialization, and the practical dimension of putting patients first.
Oct 03, 2017
With the NASH pipeline filling up fast, Mariel Metcalfe looks at what pharma companies need to do to ensure their products do not end up as also-rans in this dynamic new market segment.
Oct 03, 2017
Jayachandra Reddy and Rishit Thakkar discuss the challenges facing early entrants in the Non-alcoholic Steatohepatitis market.
Sep 22, 2017
Healthcare companies are overwhelming physicians and hospitals with brand messaging overlap. Let’s use data science to fix that, says Kevin Troyanos.
Sep 21, 2017
Pharmaceutical Executive
Despite delay in enforcement of Drug Supply Chain Security Act's new serialization requirement, getting compliant now is key.
Sep 15, 2017
A review of a recent FSP in which the CRO partner assumed clinical monitoring and site support responsibility for more than 50 ongoing trials.
Sep 04, 2017
Lisa Kerber outlines how the pharma industry can take advantage of combining new clinical data sources such as diagnostics, or lab data, with AI to deliver on the promise of improving outcomes.
Aug 29, 2017
With a new consultation from the UK’s Department of Health proposing changes to the Statutory Scheme for Pricing of Branded Medicines, what could this mean for negotiation of a successor to the Pharmaceutical Price Regulation Scheme? Leela Barham reports.
Aug 28, 2017
A long list of high priority issues requiring immediate attention on Capitol Hill leaves little time to consider drug access proposals that have limited bipartisan support, writes Jill Wechsler.
native1_300x100
lorem ipsum